NICE backs kidney cancer combination from Merck KGaA and PfizerNICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first Share XNICE backs kidney cancer combination from Merck KGaA and Pfizerhttps://pharmaphorum.com/news/nice-backs-kidney-cancer-combination-from-merck-kgaa-and-pfizer/
Pfizer ups guidance as it prepares to sell off generics divisionPfizer has cautiously upped its guidance despite second quarter figures showing a slip in sales and profitability compared Share XPfizer ups guidance as it prepares to sell off generics divisionhttps://pharmaphorum.com/news/pfizer-ups-guidance-as-it-prepares-to-sell-off-generics-division/
US places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccineThe US government has agreed to pay Pfizer and BioNTech $1.95 billion to secure access to 100 million Share XUS places $1.95 billion order for Pfizer/BioNTech’s COVID-19 vaccinehttps://pharmaphorum.com/news/us-places-1-95-billion-order-for-pfizer-biontechs-covid-19-vaccine/
Controversy as pharma execs predict profits from COVID-19 vaccinesConcerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they Share XControversy as pharma execs predict profits from COVID-19 vaccineshttps://pharmaphorum.com/news/controversy-as-pharma-execs-predict-profits-from-covid-19-vaccines/
UK announces COVID-19 vaccine deals with BioNTech/Pfizer and ValnevaThe UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses Share XUK announces COVID-19 vaccine deals with BioNTech/Pfizer and Valnevahttps://pharmaphorum.com/news/uk-announces-covid-19-vaccine-deals-with-biontechl-pfizer-and-valneva/
J&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayThe FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 Share XJ&J’s Tremfya to join crowded psoriatic arthritis market after FDA okayhttps://pharmaphorum.com/news/fda-approves-jjs-tremfya-in-psoriatic-arthritis/
FDA to fast track development of two COVID-19 vaccines from Pfizer and BioNTechTwo of Pfizer and BioNTech’s potential COVID-19 vaccines have been granted Fast Track status by the FDA, a Share XFDA to fast track development of two COVID-19 vaccines from Pfizer and BioNTechhttps://pharmaphorum.com/news/fda-to-fast-track-development-of-two-covid-19-vaccines-from-pfizer-and-biontech/
Pharma companies create $1bn fund to save antibiotic researchMore than 20 pharma companies including GlaxoSmithKline, Novartis and Pfizer have joined forces to create a $1 billion Share XPharma companies create $1bn fund to save antibiotic researchhttps://pharmaphorum.com/news/pharma-companies-create-1bn-fund-to-save-antibiotic-research/
EU regulators approve AstraZeneca’s Lynparza in pancreatic cancerThe European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation. Approval in metastatic Share XEU regulators approve AstraZeneca’s Lynparza in pancreatic cancerhttps://pharmaphorum.com/news/eu-regulators-approve-astrazenecas-lynparza-in-pancreatic-cancer/
